Solid Biosciences (NASDAQ: SLDB) RSU settlement and insider sales disclosed

Rhea-AI Filing Summary

Solid Biosciences proposed the sale of common stock under Rule 144 related to the settlement of vested restricted stock units. The filing lists 7,469 shares to be sold on 02/18/2026 as settlement of vested RSUs. It also discloses recent sales by David T. Howton totaling 61,597 shares across 12/03/2025, 02/02/2026, and 02/04/2026, with exact per‑trade share counts shown in the excerpt.

Insights

Corporate Governance Specialist

Routine Rule 144 sale and RSU settlement; no material governance change.

The filing records the settlement of 7,469 vested restricted stock units on 02/18/2026, described as issuer compensation. This is a compensation-related issuance rather than a new equity raise.

Transactions by David T. Howton totaling 61,597 shares are listed as prior sales; the excerpt provides per‑trade share counts and proceeds. These disclosures are typical for Rule 144 notices and do not on their face indicate a governance or liquidity event.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	ETRADE FINANCIAL CORPORATION 3 EDISON DRIVE ALPHARETTA GA 30005	7469	43494.23	83412695	02/18/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/18/2026	Settlement of vested restricted stock units	Issuer			7469	02/18/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Howton David T. C/O SOLID BIOSCIENCES INC. 500 Rutherford Avenue Charlestown MA 02129	Common Stock	12/03/2025	4932	25202.52
Howton David T. C/O SOLID BIOSCIENCES INC. 500 Rutherford Avenue Charlestown MA 02129	Common Stock	02/02/2026	37771	243128.15
Howton David T. C/O SOLID BIOSCIENCES INC. 500 Rutherford Avenue Charlestown MA 02129	Common Stock	02/04/2026	18894	121708.27

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Solid Biosciences' Form 144 disclose about RSU settlement?

The filing discloses the settlement of 7,469 vested restricted stock units on 02/18/2026. It states the settlement is labeled as compensation and assigned to the issuer, reflecting issuance tied to vested awards.

How many shares did David T. Howton sell recently according to the excerpt?

The excerpt shows three sales by David T. Howton totaling 61,597 shares across 12/03/2025, 02/02/2026, and 02/04/2026. Each sale includes the share count and aggregate proceeds in the entry.

Does the filing indicate proceeds go to the company or selling holders?

The excerpt labels the 7,469-share RSU settlement as Issuer compensation, indicating issuance by the company. Cash‑flow treatment for other listed sales is shown as aggregate proceeds per trade for the selling person.

Does this Rule 144 filing signal a material dilution event for SLDB?

The filing shows an issuer RSU settlement of 7,469 shares and prior insider sales; it is a compensation issuance rather than a broad offering. The excerpt does not quantify total outstanding shares or percent dilution in this text.